262 related articles for article (PubMed ID: 21436054)
1. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
Onda M; Beers R; Xiang L; Lee B; Weldon JE; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5742-7. PubMed ID: 21436054
[TBL] [Abstract][Full Text] [Related]
2. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
[TBL] [Abstract][Full Text] [Related]
3. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
Hansen JK; Weldon JE; Xiang L; Beers R; Onda M; Pastan I
J Immunother; 2010 Apr; 33(3):297-304. PubMed ID: 20445350
[TBL] [Abstract][Full Text] [Related]
4. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Weldon JE; Xiang L; Chertov O; Margulies I; Kreitman RJ; FitzGerald DJ; Pastan I
Blood; 2009 Apr; 113(16):3792-800. PubMed ID: 18988862
[TBL] [Abstract][Full Text] [Related]
5. The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.
Kawa S; Onda M; Ho M; Kreitman RJ; Bera TK; Pastan I
MAbs; 2011; 3(5):479-86. PubMed ID: 22048691
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
7. Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies.
Hu X; Zhang M; Zhang C; Long S; Wang W; Yin W; Cao Z
J BUON; 2016; 21(6):1374-1378. PubMed ID: 28039694
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxins with decreased immunogenicity and improved activity.
Pastan I; Onda M; Weldon J; Fitzgerald D; Kreitman R
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):87-90. PubMed ID: 21504287
[TBL] [Abstract][Full Text] [Related]
9. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Mazor R; Eberle JA; Hu X; Vassall AN; Onda M; Beers R; Lee EC; Kreitman RJ; Lee B; Baker D; King C; Hassan R; Benhar I; Pastan I
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8571-6. PubMed ID: 24799704
[TBL] [Abstract][Full Text] [Related]
10. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman RJ; Pastan I
Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
[TBL] [Abstract][Full Text] [Related]
11. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
[TBL] [Abstract][Full Text] [Related]
12. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
[TBL] [Abstract][Full Text] [Related]
13. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins.
Roscoe DM; Pai LH; Pastan I
Eur J Immunol; 1997 Jun; 27(6):1459-68. PubMed ID: 9209499
[TBL] [Abstract][Full Text] [Related]
14. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.
Liu W; Onda M; Lee B; Kreitman RJ; Hassan R; Xiang L; Pastan I
Proc Natl Acad Sci U S A; 2012 Jul; 109(29):11782-7. PubMed ID: 22753489
[TBL] [Abstract][Full Text] [Related]
15. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.
Liu W; Onda M; Kim C; Xiang L; Weldon JE; Lee B; Pastan I
Protein Eng Des Sel; 2012 Jan; 25(1):1-6. PubMed ID: 22101015
[TBL] [Abstract][Full Text] [Related]
16. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
[TBL] [Abstract][Full Text] [Related]
17. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.
Wang H; Dai J; Li B; Fan K; Peng L; Zhang D; Cao Z; Qian W; Wang H; Zhao J; Guo Y
Protein Expr Purif; 2008 Mar; 58(1):140-7. PubMed ID: 17950620
[TBL] [Abstract][Full Text] [Related]
18. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
[TBL] [Abstract][Full Text] [Related]
19. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
Benhar I; Pastan I
J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
[TBL] [Abstract][Full Text] [Related]
20. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]